Market closed

Stoke Therapeutics/$STOK

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Stoke Therapeutics

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Ticker

$STOK
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Bedford, United States

Employees

110
Website
www.stoketherapeutics.com

STOK Metrics

BasicAdvanced
$472M
-
-$2.07
0.95
-

$472M

0.95

$17.58

$4.09

792K

5.086

4.811

1.314

1.314

-27.50%

-52.06%

27.163

2.03

2.03

-5.37

81.08%

-14.76%

-0.37%

What the Analysts think about STOK

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.

STOK Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

STOK Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

STOK News

AllArticlesVideos
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire·6 days ago
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Business Wire·1 week ago
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STOK

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Stoke Therapeutics stock?

Stoke Therapeutics (STOK) has a market cap of $472M as of January 15, 2025.

What is the P/E ratio for Stoke Therapeutics stock?

The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of January 15, 2025.

Does Stoke Therapeutics stock pay dividends?

No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Stoke Therapeutics dividend payment date?

Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.

What is the beta indicator for Stoke Therapeutics?

Stoke Therapeutics (STOK) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.